Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. Assaf ZJF, et al. Among authors: socinski ma. Nat Med. 2023 Apr;29(4):859-868. doi: 10.1038/s41591-023-02226-6. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928816 Free PMC article.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group. Reck M, et al. Among authors: socinski ma. Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25. Lancet Respir Med. 2019. PMID: 30922878 Clinical Trial.
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.
Owen JS, Rackley RJ, Hummel MA, Roepcke S, Huang H, Liu M, Idris TA, Murugesan SMN, Marwah A, Loganathan S, Ranganna G, Barve A, Waller CF, Socinski MA. Owen JS, et al. Among authors: socinski ma. Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):675-689. doi: 10.1007/s13318-023-00855-3. Epub 2023 Oct 4. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37792130 Clinical Trial.
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW. Rodon J, et al. Among authors: socinski ma. ESMO Open. 2024 Apr;9(4):102961. doi: 10.1016/j.esmoop.2024.102961. Epub 2024 Apr 18. ESMO Open. 2024. PMID: 38640748 Free PMC article. Clinical Trial.
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak MN, Kim C, Nieva J, Swensen JJ, Spetzler D, Korn WM, Socinski MA, Raez LE, Halmos B, Ou SI. Nagasaka M, et al. Among authors: socinski ma. Transl Oncol. 2023 Oct;36:101744. doi: 10.1016/j.tranon.2023.101744. Epub 2023 Jul 27. Transl Oncol. 2023. PMID: 37516008 Free PMC article.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Fortman D, Wang H, VanderWeele R, Evans T, Herman JG, Rhee J, Reyes V, McLaughlin B, Wozniak A, Somasundaram A, Mekhail T, Socinski MA, Schulze K, Villaruz LC. Fortman D, et al. Among authors: socinski ma. Clin Lung Cancer. 2025 Jan;26(1):78-81. doi: 10.1016/j.cllc.2024.10.014. Epub 2024 Oct 30. Clin Lung Cancer. 2025. PMID: 39578170 Free article.
Correlation of safety and efficacy of atezolizumab therapy across indications.
Durán-Pacheco G, Chandler GS, Maiya V, Socinski MA, Sonpavde G, Puente J, Essioux L, Carter C, Cardona JV, Mohindra R, Naidoo J. Durán-Pacheco G, et al. Among authors: socinski ma. J Immunother Cancer. 2024 Nov 12;12(11):e010158. doi: 10.1136/jitc-2024-010158. J Immunother Cancer. 2024. PMID: 39537212 Free PMC article.
332 results